NGI co-develops R&D office, incubator with U. Iowa

Plans to build a new 80,000-sq.ft research center and business incubator.

Chris Anderson
Register for free to listen to this article
Listen with Speechify
CORALVILLE, Iowa—The National Genecular Institute (NGI) and The University of Iowa last month announced plans to build a new 80,000-square-foot research center and business incuba­tor at UI's Oakdale Research Campus. When completed in early 2008, the building will serve as a regional headquarters for Newport Beach, Calif.-based NGI while UI will gain a new Technology Innovation Center with the wet lab space it current­ly needs in order to attract life sciences companies to the area.
"There are certainly a num­ber of regions and universities in this country looking to attract these kinds of companies," says Tom Sharpe, associate VP for economic development for UI. "But we believe that our strong medi­cal school and its reputation for clinical trials, as well other areas of support, will make this very attractive for biotech companies that are just starting out."
For NGI—the R&D sub­sidiary of skin care company Dermacia—the opportunity to open a regional headquarters in Iowa was made more attractive by a number of both state and local tax incentives and financ­ing. Further, the company's CSO, Dr. Tannin Fuja, is a member of the faculty at the university.
"Being here in Iowa was cer­tainly one consideration," Fuja says. "But also very attractive to us was a cash rebate from the state that is related to the amount of dollars we spend on R&D. It was an incentive that we found in very few other states." NGI's R&D operation will focus initially on discovering and developing skin and cancer thera­peutics "at the molecular level," he notes.
In addition to the new regional HQ, NGI also announced plans to simultaneously develop a new genetic material biobanking facil­ity in nearby Iowa City. In all, NGI anticipates the cost of the two proj­ects will be upward of $26 million and will add more than 180 jobs to the local economy over the next five years.
"Our intention is to make this one of the largest biobanking facil­ities in the United States," Fuja says. "When it and our other facil­ity are completed we anticipate there will be synergies between NGI and other companies attracted to the area by the university's facil­ity and our biobanking facility." In addition, Fuja noted that there are other partner companies for Dermacia and NGI that may open up some kind of office nearby to coordinate better with NGI's Iowa-based R&D operation.

Chris Anderson

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

September 2023 issue front cover

Latest Issue  

• Volume 19 • Issue 8 • September 2023

September 2023

September 2023 Issue